Germany

Bayer HealthCare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

NEJM Publishes Data for NUBEQA® Plus Androgen Deprivation Therapy for Men with Non-Metastatic Castration-Resistant Prostate Cancer

Lead Product(s): Darolutamide

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Orion Corporation

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 09, 2020

Details:

Men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT.

Boehringer Ingelheim GmbH

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Additional Analysis of Real-World Data Confirms Sequential Gilotrif® Followed By Osimertinib Imporved Survival

Lead Product(s): Afatinib,Osimertinib

Therapeutic Area: Oncology Product Name: Gilotrif

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 10, 2020

Details:

Sequential Gilotrif® (afatinib) and osimertinib contributed to a median overall survival (OS) of nearly four years among U.S. patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer and the common resistance mutation, T790M.

MorphoSys

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

FDA Approves Monjuvi in Combination With Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Lead Product(s): Tafasitamab,Lenalidomide

Therapeutic Area: Oncology Product Name: Monjuvi

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 01, 2020

Details:

Monjuvi, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been approved under accelerated approval by the U.S. FDA based on overall response rate (ORR).

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Bayer HealthCare

NEJM Publishes Data for NUBEQA® Plus Androgen Deprivation Therapy for Men with Non-Metastatic Castration-Resistant Prostate Cancer

Boehringer Ingelheim GmbH

Additional Analysis of Real-World Data Confirms Sequential Gilotrif® Followed By Osimertinib Imporved Survival

MorphoSys

FDA Approves Monjuvi in Combination With Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)